2023
Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial
Rees C, Brousseau D, Cohen D, Villella A, Dampier C, Brown K, Campbell A, Chumpitazi C, Airewele G, Chang T, Denton C, Ellison A, Thompson A, Ahmad F, Bakshi N, Coleman K, Leibovich S, Leake D, Hatabah D, Wilkinson H, Robinson M, Casper T, Vichinsky E, Morris C. Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial. Trials 2023, 24: 538. PMID: 37587492, PMCID: PMC10433602, DOI: 10.1186/s13063-023-07538-z.Peer-Reviewed Original ResearchConceptsPediatric Emergency Care Applied Research NetworkSickle cell disease treatmentVaso-occlusive episodesSickle cell diseaseSTART trialArginine therapyIntravenous arginineLoading doseNormal saline three timesYoung adultsBlood Institute guidelinesParental opioid usePlacebo loading doseSubstantial illness burdenDisease-modifying therapiesPatient-reported outcomesDisease treatmentPhase 3Emergency medicine providersSaline three timesMulticenter research networkResearch NetworkIntravenous opioidsLast doseStudy drug
2022
Adherence to NHLBI guidelines for the emergent management of vaso‐occlusive episodes in children with sickle cell disease: A multicenter perspective
Rees C, Brousseau D, Ahmad F, Bennett J, Bhatt S, Bogie A, Brown K, Casper T, Chapman L, Chumpitazi C, Cohen D, Dampier C, Ellison A, Grasemann H, Hickey R, Hsu L, Lane P, Bakshi N, Leibovich S, Patil P, Powell E, Richards R, Sarnaik S, Weiner D, Morris C, Group and PECARN T. Adherence to NHLBI guidelines for the emergent management of vaso‐occlusive episodes in children with sickle cell disease: A multicenter perspective. American Journal Of Hematology 2022, 97: e412-e415. PMID: 36054566, PMCID: PMC9561082, DOI: 10.1002/ajh.26696.Peer-Reviewed Original Research
2018
Quantitative sensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episode
Bakshi N, Lukombo I, Belfer I, Krishnamurti L. Quantitative sensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episode. Journal Of Pain Research 2018, 11: 435-443. PMID: 29503580, PMCID: PMC5827673, DOI: 10.2147/jpr.s150066.Peer-Reviewed Original ResearchVaso-occlusive episodesQuantitative sensory testingSickle cell diseaseChronic painPain sensitivityCell diseaseSensory testingPainful vaso-occlusive episodesExperience chronic painFeasibility of recruitmentLarge prospective studiesEmergency room visitsExperimental pain sensitivityInherited blood disorderAltered painMedian agePain intensityPediatric patientsRoom visitsProspective studyInpatient hospitalizationSubset of individualsPainPatientsBlood disorders